The Combination of Zerumbone and 5-FU: A Significant Therapeutic Strategy in Sensitizing Colorectal Cancer Cells to Treatment

被引:4
|
作者
Dehghan, Razieh [1 ]
Bahreini, Fatemeh [1 ]
Najafi, Rezvan [1 ]
Saidijam, Massoud [1 ]
Amini, Razieh [1 ]
机构
[1] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Hamadan, Iran
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; UP-REGULATION; SIGNALING PATHWAY; 5-FLUOROURACIL; APOPTOSIS; SURVIVIN; CHEMOSENSITIZATION; CHEMORESISTANCE; SENSITIVITY; SUPPRESSION;
D O I
10.1155/2021/6635874
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives. Chemotherapy is considered to be essential in the treatment of patients with colorectal cancer (CRC), but drug resistance reduces its efficacy. Many patients with advanced CRC eventually show resistance to 5-fluorouracil (5-FU) therapy. Synergistic and potentiating effects of combination therapy, using herbal and chemical drugs, can improve patients' response. Zerumbone (ZER), which is derived from ginger, has been studied for its growth inhibitory function in various types of cancer. Methods. The cytotoxic effects of ZER and 5-FU alone and their combination, on the SW48 and HCT-116 cells, were examined, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). The mRNA and protein levels of beta-catenin, survivin, and vimentin were measured in treated CRC cells, using qRT-PCR and western blot. Colony formation assay, scratch test, and flow cytometry were performed to detect the changes of proliferation, migration, and apoptosis. Key Findings. In HCT-116- and SW48-treated cells, the proliferation, the gene and protein expression levels of the markers, the migration, the colony formation, and the survival rates were all significantly reduced compared to the control groups, and the sharpest decline was observed in the 5-FU+ZER treatment groups. Conclusions. Combination therapy has shown promising results in CRC cells, especially in drug-resistant cells.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4
    Azar, Mohammad Reza Mohammad Hoseini
    Aghazadeh, Hamed
    Mohammed, Halgurd Nadhim
    Sara, Mehdi Rezai Seghin
    Hosseini, Arezoo
    Shomali, Navid
    Tamjidifar, Rozita
    Tarzi, Saeed
    Mansouri, Mahmoud
    Sarand, Sahar Pashaei
    Marofi, Faroogh
    Akbari, Morteza
    Xu, Huaxi
    Shotorbani, Siamak Sandoghchian
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 92
  • [42] RETRACTED: Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer (Retracted Article)
    Tan, Xiao
    Zhang, Zhongqiang
    Liu, Ping
    Yao, Hongliang
    Shen, Liangfang
    Tong, Jing-Shan
    CELL DEATH & DISEASE, 2020, 11 (12)
  • [43] Effective Treatment of Advanced Colorectal Cancer by Rapamycin and 5-FU/Oxaliplatin Monitored by TIMP-1
    Wagner, Markus
    Roh, Vincent
    Strehlen, Michael
    Laemmle, Alexander
    Stroka, Deborah
    Egger, Bernhard
    Trochsler, Markus
    Hunt, Kelly K.
    Candinas, Daniel
    Vorburger, Stephan A.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (10) : 1781 - 1790
  • [44] MiR-106a-5p promotes 5-FU resistance and the metastasis of colorectal cancer by targeting TGFβR2
    Liu, Jian
    Huang, Yanqin
    Wang, Hongqian
    Wu, Denghai
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (12): : 5622 - 5634
  • [45] Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells
    Qayum, Arem
    Magotra, Asmita
    Shah, Syed Mohmad
    Nandi, Utpal
    Sharma, P. R.
    Shah, Bhahwal Ali
    Singh, Shashank Kumar
    HELIYON, 2022, 8 (04)
  • [46] Overexpression of sortilin is associated with 5-FU resistance and poor prognosis in colorectal cancer
    Blondy, Sabrina
    Talbot, Hugo
    Saada, Sofiane
    Christou, Niki
    Battu, Serge
    Pannequin, Julie
    Jauberteau, Marie-Odile
    Lalloue, Fabrice
    Verdier, Mireille
    Mathonnet, Muriel
    Perraud, Aurelie
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (01) : 47 - 60
  • [47] An RNA damage response network mediates the lethality of 5-FU in colorectal cancer
    Chen, Jung-Kuei
    Merrick, Karl A.
    Kong, Yi Wen
    Izrael-Tomasevic, Anita
    Eng, George
    Handly, Erika D.
    Patterson, Jesse C.
    Cannell, Ian G.
    Suarez-Lopez, Lucia
    Hosios, Aaron M.
    Dinh, Anh
    Kirkpatrick, Donald S.
    Yu, Kebing
    Rose, Christopher M.
    Hernandez, Jonathan M.
    Hwangbo, Haeun
    Palmer, Adam C.
    Heiden, Matthew G. Vander
    Yilmaz, Omer H.
    Yaffe, Michael B.
    CELL REPORTS MEDICINE, 2024, 5 (10)
  • [48] Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer
    Zhu, Yiping
    Li, Kai
    Zhang, Jieling
    Wang, Lu
    Sheng, Lili
    Yan, Liang
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 11271 - 11283
  • [49] Combinational inhibition of EGFR and YAP reverses 5-Fu resistance in colorectal cancer
    Huang, Changhao
    Chen, Zihua
    Yang, Chen
    Chen, Lu
    Lai, Chen
    Zhang, Yingying
    Yuan, Weijie
    Jeong, Ji-Hak
    JOURNAL OF CANCER, 2020, 11 (18): : 5432 - 5439
  • [50] A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer
    Fakih, M. G.
    Groman, A.
    McMahon, J.
    Wilding, G.
    Muindi, J. R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 743 - 751